D. D. Groot

University of Groningen RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer

S. Sleijfer, H. Verheul, M. Jansen, 2019 .

Consequence of Restaging After Neoadjuvant Treatment for Locally Advanced Rectal Cancer

K. Havenga, J. Burgerhof, E. Wiegman, 2015, Annals of Surgical Oncology.

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Joon-Oh Park, H. Harputluoglu, G. Brandi, 2023, The Lancet.

Functional Genomic mRNA ProFIling of Colorectal Adenomas : IDeNTIFICATION and in vivo Validation of CD 44 and Splice Variant CD 44 v 6 as Molecular Imaging Targets Theranostics

R. Fehrmann, A. Karrenbeld, V. Orian-Rousseau, 2017 .

Effect of extending the original eligibility criteria for the “CROSS” neoadjuvant chemoradiotherapy on toxicity and survival in esophageal cancer.

G. Hospers, J. Plukker, J. Hulshoff, 2017 .